

1 **Pandemic inequity in a megacity: a multilevel analysis of individual, community and**
2 **health care vulnerability risks for COVID-19 mortality in Jakarta, Indonesia**

3
4 **Authors:** Henry Surendra PhD^{1,2}, Ngabila Salama MD³, Karina D Lestari BSc¹, Verry Adrian
5 MD³, Widyastuti MD³, Dwi Oktavia MD³, Rosa N Lina MPH¹, Bimandra A Djaafara MSc^{1,4},
6 Ihsan Fadilah MSc¹, Rahmat Sagara MSc¹, Lenny L Ekawati MPH^{1,5}, Ahmad Nurhasim
7 MSc⁶, Riris A Ahmad PhD², Aria Kekalih PhD⁷, Prof Ari F Syam MD⁷, Anuraj H Shankar
8 ScD^{1,5}, Prof Guy Thwaites MD^{5,8}, Prof J. Kevin Baird PhD^{1,5}, Raph L. Hamers MD^{1,5,7}, Iqbal
9 RF Elyazar PhD¹

10

11 ¹ Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia

12 ² Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas
13 Gadjah Mada, Yogyakarta, Indonesia

14 ³ DKI Jakarta Health Office, Jakarta, Indonesia

15 ⁴ MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease
16 Epidemiology, Imperial College London, London, United Kingdom

17 ⁵ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University
18 of Oxford, United Kingdom

19 ⁶ The Conversation Indonesia, Jakarta, Indonesia

20 ⁷ Faculty of Medicine University of Indonesia, Jakarta, Indonesia

21 ⁸ Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City,
22 Vietnam

23

24 **Corresponding author:**

25 Henry Surendra PhD

26 Eijkman-Oxford Clinical Research Unit

27 Jalan Diponegoro 69

28 10430 Jakarta, Indonesia.

29 Phone: (021) 3910414

30 Email: hsurendra@eocru.org; henrysurendra.15@gmail.com

31

32

33

34

35

36

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 **Abstract**

38 **Background** The 33 recognized megacities comprise approximately 7% of the global
39 population, yet account for 20% COVID-19 deaths. The specific inequities and other factors
40 within megacities that affect vulnerability to COVID-19 mortality remain poorly defined. We
41 assessed individual, community-level and health care factors associated with COVID-19-
42 related mortality in a megacity of Jakarta, Indonesia, during two epidemic waves spanning
43 March 2, 2020, to August 31, 2021.

44 **Methods** This retrospective cohort included all residents of Jakarta, Indonesia, with PCR-
45 confirmed COVID-19. We extracted demographic, clinical, outcome (recovered or died),
46 vaccine coverage data, and disease prevalence from Jakarta Health Office surveillance
47 records, and collected sub-district level socio-demographics data from various official sources.
48 We used multi-level logistic regression to examine individual, community and sub-district-level
49 health care factors and their associations with COVID-19-mortality.

50 **Findings** Of 705,503 cases with a definitive outcome by August 31, 2021, 694,706 (98.5%)
51 recovered and 10,797 (1.5%) died. The median age was 36 years (IQR 24–50), 13.2%
52 (93,459) were <18 years, and 51.6% were female. The sub-district level accounted for 1.5%
53 of variance in mortality ($p < 0.0001$). Individual-level factors associated with death were older
54 age, male sex, comorbidities, and, during the first wave, age <5 years (adjusted odds ratio
55 (aOR) 1.56, 95%CI 1.04-2.35; reference: age 20-29 years). Community-level factors
56 associated with death were poverty (aOR for the poorer quarter 1.35, 95%CI 1.17-1.55;
57 reference: wealthiest quarter), high population density (aOR for the highest density 1.34,
58 95%CI 1.14-2.58; reference: the lowest), low vaccine coverage (aOR for the lowest coverage
59 1.25, 95%CI 1.13-1.38; reference: the highest).

60 **Interpretation** In addition to individual risk factors, living in areas with high poverty and
61 density, and low health care performance further increase the vulnerability of communities to
62 COVID-19-associated death in urban low-resource settings.

63

64 **Funding** Wellcome (UK) Africa Asia Programme Vietnam (106680/Z/14/Z).

65

66

67

68

69

70

71

72

73 **Research in context**

74

75 **Evidence before this study**

76 We searched PubMed on November 22, 2021, for articles that assessed individual,
77 community, and healthcare vulnerability factors associated with coronavirus disease 2019
78 (COVID-19) mortality, using the search terms (“novel coronavirus” OR “SARS-CoV-2” OR
79 “COVID-19”) AND (“death” OR “mortality” OR “deceased”) AND (“community” OR “social”)
80 AND (“healthcare” OR “health system”). The 33 recognized megacities comprise
81 approximately 7% of the global population, yet account for 20% COVID-19 deaths. The
82 specific inequities and other factors within megacities that affect vulnerability to COVID-19
83 mortality remain poorly defined. At individual-level, studies have shown COVID-19-related
84 mortality to be associated with older age and common underlying chronic co-morbidities
85 including hypertension, diabetes, obesity, cardiac disease, chronic kidney disease and liver
86 disease. Only few studies from North America, and South America have reported the
87 association between lower community-level socio-economic status and healthcare
88 performance with increased risk of COVID-19-related death. We found no studies have been
89 done to assess individual, community, and healthcare vulnerability factors associated with
90 COVID-19 mortality risk, especially in lower-and middle-income countries (LMIC) where
91 accessing quality health care services is often challenging for substantial proportions of
92 population, due to under-resourced and fragile health systems. In Southeast Asia, by
93 November 22, 2021, COVID-19 case fatality rate had been reported at 2.2%
94 (23,951/1,104,835) in Vietnam, 1.7% (47,288/2,826,853) in Philippines, 1.0%
95 (20,434/2,071,009) in Thailand, 1.2% (30,063/2,591,486) in Malaysia, 2.4% (2,905/119,904)
96 in Cambodia, and 0.3% in Singapore (667/253,649). Indonesia has the highest number of
97 COVID-19 cases and deaths in the region, reporting 3.4% case fatality rate (143,744
98 /4,253,598), with the highest number of cases in the capital city of Jakarta. A preliminary
99 analysis of the first five months of surveillance in Jakarta found that 497 of 4265 (12%)
100 hospitalised patients had died, associated with older age, male sex; pre-existing hypertension,
101 diabetes, or chronic kidney disease; clinical diagnosis of pneumonia; multiple (>3) symptoms;
102 immediate intensive care unit admission, or intubation.

103 **Added value of this study**

104 This retrospective population-based study of the complete epidemiological surveillance data
105 of Jakarta during the first eighteen months of the epidemic is the largest studies in LMIC to
106 date, that comprehensively analysed the individual, community, and healthcare vulnerability
107 associated with COVID-19-related mortality among individuals diagnosed with PCR-confirmed
108 COVID-19. The overall case fatality rate among general population in Jakarta was 1.5%
109 (10,797/705,503). Individual factors associated with risk of death were older age, male sex,

110 comorbidities, and, during the first wave, age <5 years (adjusted odds ratio (aOR) 1.56, 95%CI
111 1.04-2.35; reference: age 20-29 years). The risk of death was further increased for people
112 living in sub-districts with high rates of poverty (aOR for the poorer quarter 1.35, 95%CI 1.17-
113 1.55; reference: wealthiest quarter), high population density (aOR for the highest density 1.34,
114 95%CI 1.14-2.58), and low COVID-19 vaccination coverage (aOR for the lowest coverage
115 1.25, 95%CI 1.13-1.38; reference: the highest).

116 **Implications of all available evidence**

117 Differences in socio-demographics and access to quality health services, among other factors,
118 greatly influence COVID-19 mortality in low-resource settings. This study affirmed that in
119 addition to well-known individual risk factors, community-level socio-demographics and
120 healthcare factors further increase the vulnerability of communities to die from COVID-19 in
121 urban low-resource settings. These results highlight the need for accelerated vaccine rollout
122 and additional preventive interventions to protect the urban poor who are most vulnerable to
123 dying from COVID-19.

124

125 **Background (Word count: 3500 words)**

126

127 There are currently 33 megacities, defined by the United Nations Department of Economic
128 and Social Affairs as cities with a population of at least 10 million persons¹. Megacities
129 comprise 8% of the global population, yet account for approximately 20% of all COVID-19
130 deaths². Megacities often contain high levels of inequity with regard to income, housing,
131 sanitation, transportation, population density, basic health care, and other factors. The
132 important role of health inequity in the spread and mortality of epidemics has been known from
133 influenza in 1918 to Ebola in 2014³⁻⁷. The severity of illness and clinical outcomes can be
134 affected by the concentration of comorbidities in susceptible groups in communities^{3,4,8}, and
135 through disparities of access to health care for preventive measures or prompt diagnosis and
136 treatment. Ensuring health equity, especially in megacities experiencing massive urbanization
137 and mobility is essential for the current and future global health threats.

138

139 In the context of the ongoing pandemic, understanding community-level risk factors
140 associated with the mortality is very important to guide policymaking and target public health
141 and clinical interventions, particularly in the context of fragile public health systems. At
142 individual-level, older age and pre-existing chronic comorbidities have been consistently
143 reported as the main risk factors of COVID-19-related mortality across different settings⁹⁻¹³.
144 At the community-level, recent findings in US, Chile and Brazil suggested that COVID-19
145 mortality was concentrated in groups with higher socio-demographics vulnerability¹⁴⁻¹⁸.

146 However, there is a general scarcity of data in LMIC assessing the influence of community-
147 level socio-demographics factors on COVID-19-related mortality.

148

149 Indonesia, the world's fourth most populous country (population 274 million), is a lower-middle
150 income country (LMIC) featuring great geographic, cultural and socio-economic diversity
151 across the archipelago. For example, the 2019 human development index (HDI) ranged from
152 0.32 in Nduga District, Papua to 0.87 in Yogyakarta city, Yogyakarta¹⁹. Indonesia has suffered
153 the highest number of COVID-19 confirmed cases and deaths in Southeast Asia, second only
154 to India in all of Asia²⁰, at 4,253,598 cases and 143,744 deaths (3.4% case fatality rate (CFR))
155 up to November 22, 2021²¹, of which 20% (863,482) of cases and 9.4% (13,574) of deaths
156 occurred in its capital Jakarta, a megacity (7,659 Km², and estimated population 10.6 million)
157 that features stark health inequalities and socio-demographic heterogeneity. The first SARS-
158 CoV-2 epidemic wave occurred from March 2 2020 to April 30 2021, and a more intense
159 second wave dominated by Delta variant peaked in July 2021^{22,23}.

160

161 As in many LMIC, accessing quality health care services is challenging to substantial
162 proportions of the Indonesian population, due to under-resourced and fragile health systems²⁴.
163 The 2018 public health development index (PHDI) ranges from 35% in Paniai district, Papua
164 province to 75% in Gianyar district, Bali province. Within the province-level administration area
165 called the Special Capital City Area Jakarta (*Daerah Khusus Ibukota*, DKI Jakarta), the PHDI
166 ranged from 64% in North Jakarta to 68% in East Jakarta districts. However, the five districts
167 of DKI Jakarta (North, East, West, South and Central) are highly heterogeneous socio-
168 demographically and little is known regarding the capacity and performance of public health
169 systems at sub-district level. That heterogeneity and the large number of COVID-19 cases
170 and deaths during the first and second wave of the epidemic in DKI Jakarta provides insights
171 directly relevant to the national public health response to the COVID-19 crisis, as well as other
172 LMIC settings. In this study, we assessed individual, community-level and health care
173 vulnerability among the 44 sub-districts of DKI Jakarta and how those factors were associated
174 with COVID-19-related mortality during the first 18 months of the epidemic in that province
175 (March 2020 through August 2021).

176

177 **Methods**

178

179 **Study design and participants**

180 This was a retrospective cohort study of all adults and children diagnosed with PCR-confirmed
181 SARS-CoV-2 infection (COVID-19 cases) in DKI Jakarta, Indonesia, recorded by the DKI
182 Jakarta Health Office, who either died or recovered between March 2, 2020 and August 31,

183 2021. We restricted the analysis to DKI Jakarta residents to enable robust estimations of
184 community-level risk factors and individual outcomes (deceased vs recovered) of cases living
185 in the corresponding sub-district (Figure 1A). In accordance with Indonesia's national COVID-
186 19 guidelines²⁵, confirmatory SARS-CoV-2 PCR testing was conducted on naso-and/or
187 oropharyngeal swab specimens in COVID-19 reference laboratories.

188

189 **Data collection and operational definitions**

190 Individual-level data were collected from all cases who lived in any of 44 sub-districts in DKI
191 Jakarta. Each sub-district public health facility had designated epidemiologists and
192 surveillance officers responsible for epidemiological investigations using an official COVID-19
193 case investigation form capturing demographical and clinical data of each confirmed case.
194 Completed forms were submitted to the DKI Jakarta Health Office for cleaning and verification
195 (checking for completeness, inconsistency, error, and duplication) and entered into a
196 surveillance database. We extracted data regarding SARS-CoV-2 PCR testing, hospital
197 admission, and outcomes (recovered or deceased), along with age, sex, and pre-existing
198 comorbidities (based on clinical assessment or cases self-report)²⁵.

199

200 Sub-district-level data (community-level risk factors) were collected from official government
201 websites. Data on number of population, population density (number of residents per square
202 kilometre (Km²), number of neighbourhoods with poor sanitation, number of nurses, and
203 number of medical doctors were collected from the DKI Jakarta Government Integrated Data
204 Portal²⁶. Data on the number of individuals categorised as poorest (the lowest tenth of the
205 national level of poverty) were obtained from the National Team for the Acceleration of Poverty
206 Reduction, and used to calculate proportion of poorest individuals by sub-district²⁷. Population
207 density, poverty, and proportion of poor sanitation areas were used to describe socio-
208 demographic vulnerability. Data on COVID-19 vaccine coverage, universal child immunization
209 coverage, all-cause mortality among under 5 years population, prevalence of hypertension,
210 diabetes, and tuberculosis were collected from the DKI Jakarta Health Office surveillance
211 records. Doctor-population ratio (number of doctors per 10,000 population in 2020), nurse-
212 population ratio (number of nurses per 10,000 population in 2020), COVID-19 vaccine
213 coverage (proportion of individuals received two-dose of COVID-19 vaccine per August 31
214 2021), universal child immunization coverage (proportion of children received complete
215 dosage of government mandatory vaccination), all-cause mortality among under 5 years
216 population (proportion of all of deaths per 1000 under 5 years population), prevalence of
217 hypertension in 2019 (proportion of cases per 100 population), prevalence of diabetes in 2019
218 (proportion of cases per 100 population), and prevalence of tuberculosis in 2019 (proportion
219 of cases per 100 population) by sub-district were used to describe health care vulnerability.

220 **Statistical analysis**

221

222 Numeric values of each community-level risk factors were categorised into quarters, i.e., below
223 25th percentile (quarter 1), 25-50th percentile (quarter 2), 50-75th percentile (quarter 3) and
224 above 75th percentile (quarter 4). Descriptive statistics included proportions for categorical
225 variables and medians and interquartile ranges (IQRs) for continuous variables. We used the
226 Mann-Whitney U test, χ^2 test, or Fisher's exact test to compare characteristics between
227 deceased and recovered cases. We set statistical significance at 0.05, and all tests were two
228 sided.

229

230 We used bivariable and multivariable multi-level logistic regression models to determine the
231 risk of death, expressed as odds ratio (OR) with 95% confidential intervals (CI). Sub-district
232 was treated as the random effect variable to adjust for clustering of observations within sub-
233 districts. We did null model analysis (no predictor was added) and the result justified the use
234 of the multi-level models. We excluded cases from two sub-districts with insufficient sample
235 size (Kepulauan Seribu Selatan and Utara). All independent variables with p-value <0.10 in
236 bivariable analysis were included in the multivariable models. Final model selection was
237 informed by intra class correlation postestimation test. We used interaction terms to examine
238 potential effect modification by age, sex, and time. In the presence of interaction, the stratum-
239 specific OR and 95% CI were calculated, adjusting for other variables with p-value <0.10 in
240 bivariable analysis. Additionally, we used a restricted cubic spline mixed effect regression to
241 model the OR of death over time.

242

243 There was a substantial proportion of missing data for chronic comorbidities (58%). Missing-
244 indicator analysis by risk factor stratification and by regression analysis identified bias of
245 missing data with respect to mortality, thus we additionally conducted analysis to assess
246 sensitivity of risk factor identification due to missing data. We performed multi-level logistic
247 regression analysis with multiple imputations (100 imputed datasets), treating sub-district as
248 random effect variable. Age, sex, and outcome were included as independent variables in
249 imputing the comorbidities variable. All statistical analyses were done in Stata/MP 17.1
250 (StataCorp, College Station, TX, USA). This study is reported as per Strengthening the
251 Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

252

253 **Ethics**

254 This study was approved by the Health Research Ethics Committee of the National Institute
255 of Health Research and Development, Ministry of Health Indonesia

256 (LB.02.01/2/KE.643/2021). The requirement for patient consent was waived as this was a
257 secondary analysis of anonymised routine surveillance data²¹.

258

259 **Role of the funding source**

260 The funder of the study had no role in study design, data collection, data analysis, data
261 interpretation, or writing of the report. The corresponding author had full access to all of the
262 data and the final responsibility to submit for publication. All authors were not precluded from
263 accessing data in the study, and accepted responsibility to submit for publication.

264

265 **Results**

266

267 Between March 2 and August 31, 2021, a total of 842,646 PCR-confirmed COVID-19 cases
268 were recorded by the DKI Jakarta Health Office (Figure 1). Of those, 709,357 (84.2%) lived in
269 DKI Jakarta and 705,503 (99.5%) had reached a definitive outcome before September 1,
270 2021, i.e., those deceased or recovered and were included in this analysis. The 2392 (0.3%)
271 individuals who were still hospitalised, and 1462 (0.2%) who were in self-isolation were not
272 included in analysis. The study flow chart and completeness of key data are presented in
273 Figure 1B.

274

275 Table 1 presents the characteristics of the 705,503 cases included in the analysis. The median
276 age was 36 years (IQR 24-50, range 0.1-121), with 93,459 (13.2%) under 18 years, and
277 364,133 (51.6%) were women, and 233,025 (33.0%) had been hospitalised due to COVID-19.
278 The second wave of the pandemic comprised 372,688 (53.7%) cases, with 288,228 (40.9%)
279 having no chronic comorbidities, 4,974 (0.7%) with at least one comorbidity, and 412,301
280 (58.4%) with unknown status of comorbidities.

281

282 Regarding socio-demographics, 150,028 (21.6%) cases lived in sub-districts with the highest
283 population density (22,578-50,829 people/Km²), and 175,249 (24.9%) with the highest
284 proportion of poor population (3.6-8.8%). Regarding health care, 190,502 (27.0%) lived in the
285 lowest COVID-19 vaccine coverage (33.0-36.1%), 181,890 (25.8%) lived in the highest
286 hypertension prevalence (13.6-33.0%), 184,111 (26.1%) in the highest diabetes prevalence
287 (3.2-5.4%), 163,400 (23.2%) in the highest tuberculosis prevalence (0.5-2.4%), and 173,999
288 (25.1%) in the highest childhood vaccine coverage (98.9-100.0%) (See Table 1 for details).

289

290 Of the 705,503 cases with a known outcome, 694,706 (98.5%) had recovered, 10,797 (1.5%)
291 had died, and 105 (1.0%) had been declared dead at home and without hospitalisation. The
292 highest numbers of cases (39% of 705,503), and deaths (25% of 10,797) were observed in

293 July 2021 (Supplementary Figure 1A). Although a large majority of deaths (76%, 8203) was
294 50 years or older, death occurred across all age groups. Age-specific CFRs were 0.2%
295 (47/21,793) for <5 years; 0.1% (16/23,070) for 5-9 years; 0.1% (72/66,514) for 10-19 years;
296 0.2% (311/149,267) for 20-29 years; 0.5% (692/146,900) for 30-39 years; 1.2%
297 (1455/121,454) for 40-49 years; 3.2% (3115/98,934) for 50-59 years; 5.4% (2827/52,776) for
298 60-69 years; and 9.1% (2261/24,761) for ≥ 70 years (Supplementary Table 1 and
299 Supplementary Figure 1B).

300

301 Compared to recovered cases, deceased cases were older (median 59 vs 35 years); more
302 likely to be males (1.8% vs 1.3%), to have one or more comorbidities (9.4% vs 1.0%), to be
303 infected in the first wave (1.9% vs 1.2%), and to live in sub-districts with higher population
304 density (highest density: 1.7% vs lowest density: 1.4%), higher poverty (highest: 1.6% vs
305 lowest: 1.4%); higher nurse-population ratio (lowest: 1.6% vs highest: 1.5%); and lower
306 vaccine coverage (lowest: 1.7% vs highest: 1.4%) (Table 1). Compared with the first wave,
307 there was a notable decrease in CFRs across sub-districts during the second wave of the
308 epidemic (Figure 2E-F, and Figure 3B). Moreover, the sub-districts with higher population
309 density, poverty, and lower vaccine coverage tended to be the sub-districts with higher CFR
310 (Figure 2A-D, and Figure 3C).

311

312 In bivariable analysis (Table 2), the risk of death was significantly associated with older age,
313 male sex, comorbidities, first wave, and higher sub-district population density, poverty, higher
314 prevalence of tuberculosis, all-cause mortality among under 5 years, and lower COVID-19
315 vaccine coverage.

316

317 In the final multivariable multi-level logistic regression model (Figure 4A), the risk of death was
318 increased for age groups 30-39 years (aOR 1.94, 95%CI 1.62-2.33), 40-49 years (aOR 4.51,
319 95%CI 3.82-5.33), 50-59 years (aOR 12.65, 95%CI 10.80-14.81), 60-69 years (aOR 18.64,
320 95%CI 15.87-21.89), ≥ 70 years (aOR 32.91, 95%CI 27.97-38.72) compared to 20-29 years;
321 for males (aOR 1.29, 95%CI 1.24-1.34); for individuals with at least one comorbidity (aOR
322 3.96, 95%CI 3.56-4.41); for residents of sub-districts with highest population density (aOR
323 1.34, 95%CI 1.14-1.58, reference: lowest density), higher poverty (Q3) (aOR 1.35, 95%CI
324 1.17-1.55, reference: lowest poverty), and with lowest vaccine coverage (aOR 1.25, 95%CI
325 1.13-1.38, reference: highest coverage). We found no associations with proportion of poor
326 sanitation areas, doctor-population ratio, nurse-population ratio, prevalence of hypertension,
327 diabetes, and tuberculosis ($p > 0.05$ each). The sensitivity analysis revealed similar findings,
328 suggesting there was no significant bias introduced by missing data in our dataset; it also
329 suggested that the risk of death was increased for cases who had at least one comorbidity

330 (aOR 4.25, 95%CI 3.81-4.75) compared to those who had no comorbidity (Supplementary
331 Table 2).

332

333 We found that the effect of age was modified by time (first wave), and poverty was modified
334 by population density ($p < 0.0001$). Although higher age was associated with increased risk of
335 death, we found that the risk of death was higher for children 0-4 years (aOR 1.56 95%CI
336 1.04-2.35) compared to adult age 20-29 years in the first pandemic wave, but not in the second
337 wave (Supplementary Table 3). We found that mortality risk significantly decreased over time
338 especially for children 0-9 years (Figure 4B). In addition, we found that the risk of death was
339 higher for sub-districts with highest level of poverty and density compared to sub-districts with
340 lowest poverty and density (aOR 1.27, 95%CI 1.10-1.47) (Supplementary Table 4). Sex was
341 not found to be an effect modifier in the final model.

342

343 **Discussion**

344

345 This retrospective study described the complete epidemiological surveillance data of PCR-
346 confirmed COVID-19 cases in DKI Jakarta, including 705,503 adults and children living in 44
347 sub-districts, during two epidemic waves spanning the first 18 months of the SARS-CoV-2
348 transmission in Indonesia. This analysis represents the largest reported case series from any
349 LMIC to date. The overall CFR was 1.2% (10,797/705,503), and deaths occurred across all
350 ages. People aged less than 50 accounted for 75% of cases and 81% of the population, while
351 those older than 50 accounted for 76% of deaths but only 19% of the population. Mortality
352 increased with age, from 1.2% in cases aged 40-49 years to 9.1% in patients aged ≥ 70 years.
353 In line with previous reports from various settings, the strongest independent risk factors of
354 deaths were older age, male sex, and the presence of one or more chronic comorbidities.
355 Important novel findings were that sub-district-level socio-demographic factors, especially high
356 population density and poverty, and health care factors, especially low COVID-19 vaccine
357 coverage, further increased the risk of COVID-19-related death in metropolitan Jakarta.

358

359 A previous US study conducted in the early phase of the pandemic showed a significant
360 association between household crowding and COVID-19 outcomes¹⁸; counties with the
361 highest household crowding had a nearly 2-fold higher COVID-19 mortality rate than counties
362 with the lowest crowding. Concordant with that study, we found that residents in sub-districts
363 with the highest population density had a 34% higher risk of death than those residing in sub-
364 districts with the lowest density. This finding typically relates to crowded urban communities
365 who have the lowest standards of sanitation and waste management, and housing along flood-

366 prone riverbanks. These sub-districts are also known to have relatively higher prevalence of
367 non-communicable diseases such as hypertension and diabetes, and poverty-related
368 infectious disease such as tuberculosis (Supplementary Table 5), which are well-established
369 risk factors for worse COVID-19-associated clinical outcomes²⁸. Reducing mortality in these
370 areas may require comprehensive interventions such as improving diagnosis and case
371 management of those known non-communicable and infectious diseases, as well as ensuring
372 high COVID-19 vaccine coverage, and a sustainable social security network that may reduce
373 vulnerability of these communities.

374
375 Socio-economic status including poverty has been associated with COVID-19 mortality in
376 previous studies from South America¹⁵⁻¹⁷. In Chile, living in municipalities with lower socio-
377 economic status was associated with increased risk of COVID-19-related mortality among
378 general population¹⁵. In Brazil, living in a region with lower socio-economic status was
379 associated with higher mortality risk among children hospitalised with COVID-19^{16,17}. Similar
380 to those studies, we found that the risk of death was 40% higher for resident of sub-districts
381 with higher poverty (quarter 3) relative to those of lowest poverty. The interaction between
382 poverty and population density also revealed that the risk of death was 30% higher for sub-
383 districts with highest level of poverty and density compared to sub-districts with lowest poverty
384 and density. Urban crowding and poverty impose very many disadvantages to health, here
385 shown to include elevated risk of death as a consequence of SARS-CoV-2 infection.

386
387 The risk of COVID-19-related death in DKI Jakarta was 25% higher for resident of sub-districts
388 with the lowest vaccine coverage (33-36%), compared to resident of sub-districts with the
389 highest COVID-19 vaccine coverage (41-51%) as of August 31, 2021. This finding indicates
390 that sub-districts with higher vaccine coverage can significantly reduce risk of mortality
391 compared to those sub-districts with lower vaccine coverage. A previous study from Brazil
392 reported that rapid scaling up of vaccination coverage among elderly Brazilians was
393 associated with significant declines in relative mortality compared to younger individuals, in a
394 setting where the gamma variant predominated²⁹. Moreover, a recent modelling study
395 estimated that the US states of Florida and Texas could have averted more than 95,000
396 hospital admissions and 22,000 deaths, if they had reached the vaccination coverage
397 achieved by the top five states and continued at the same pace until August 31, 2021³⁰. Those
398 observations, corroborated in DKI Jakarta by the present study, highlight the health dividend
399 of reduced mortality with rapid vaccination roll outs targeting the most vulnerable in reducing
400 COVID-19-related deaths. As per November 23, 2021, two-dose COVID-19 vaccination
401 coverage was 99.4% (8,887,770/8,941,211 targeted population) in DKI Jakarta, and 43.2%
402 (89,892,161/208,265,720 targeted population) in Indonesia.

403

404 Consistent with evidence from previous studies across various settings, our findings affirm
405 that older age, male sex and presence of underlying comorbidities were associated with higher
406 risk of COVID-19-related mortality in the general population of DKI Jakarta, Indonesia^{11–13,15,17}.
407 The finding that children aged under 5 years old were 60% more likely to die during the first
408 wave but not during the second, especially for those living in vulnerable districts, indicates that
409 the youngest populations have been suffering most from gaps in access to health services,
410 clinical management, and community support during the early epidemic response. Similar
411 findings were reported from Brazil, where the risk of in-hospital death was 1.4-fold higher for
412 children aged <2 years compared to those aged 2–11 years, those with comorbidities and
413 living in areas with lower socio-economics status¹⁶. Hypertension and diabetes have each
414 been associated with elevated risk of COVID-19 death in this setting¹³.

415

416 This study had some limitations. The retrospective design and reliance on routine surveillance
417 data meant that, for some key baseline variables, data were incomplete or uniformly
418 unavailable (e.g., type of comorbidities and disease severity classification). As in many other
419 settings, the individual-level socio-demographics data were not recorded in the current
420 Indonesia's national database²². Comorbidities were often self-reported or could be under-
421 diagnosed, potentially resulting in underreporting and hence underestimation of effect sizes.
422 Details on supportive care and treatment received were also not available for this analysis.
423 There are several other relevant socio-demographics variables such as human development
424 index and public health development index that may represent population and health system
425 vulnerability²⁴ but were only available at the district level, and were not included in our analysis.
426 However, our analysis included all available key variables that compose those indicators
427 (prevalence of infectious and non-communicable diseases, health care workers-population
428 ratio, universal child immunization, and all-cause mortality among under 5 years old
429 population), therefore enhancing credibility of our findings.

430

431 In conclusion, individual-level risk factors associated with COVID-19 mortality in DKI Jakarta,
432 Indonesia are broadly similar to those in more developed settings, dominated by advanced
433 age and comorbidities. At the community-level, our analysis suggested that COVID-19
434 disproportionately affected people living in areas of high population density, poverty, and lower
435 vaccination coverage. These findings indicate that vulnerability to death associated with
436 COVID-19 includes not only the elderly and comorbid, but also the urban poor. This finding
437 may inform decisions on health resource allocation against COVID-19 delivering the greatest
438 possible health dividends by prioritising interventions, including vaccination, for the most
439 vulnerable communities. Future nationwide studies assessing individual, community, and

440 health care capacity vulnerability associated with COVID-19-related mortality are needed to
441 better understand the COVID-19 impact and to better tailor interventions to prioritise the most
442 vulnerable communities.

443

444 **Contributors**

445 HS designed the study, did the analysis, and had full access to all of the data in the study and
446 take responsibility for the integrity of the data and the accuracy of the data analysis. NS, VA,
447 W, and DO did data collection and verification. KDL did the data cleaning. HS, AHS, RLH,
448 JKB, and IRFE, contributed to the analysis and drafted the paper. All authors critically revised
449 the manuscript for important intellectual content and all authors gave final approval for the
450 version to be published.

451

452 **Conflict of interests**

453 We declare no competing interests.

454

455 **Data sharing statement**

456 After publication, the datasets used for this study will be made available to others on
457 reasonable requests to the corresponding author, including a detailed research proposal,
458 study objectives and statistical analysis plan. Deidentified participant data will be provided
459 after written approval from the corresponding author and the DKI Jakarta Health Office.

460

461 **Acknowledgments**

462 This work was funded by the Wellcome (UK) Africa Asia Programme Vietnam
463 (106680/Z/14/Z). We acknowledge all health care workers involved in the care for the COVID-
464 19 patients, as well as those involved in the field data collection. Data cleaning was supported
465 by funding from the Open Society Foundations.

466 **References**

- 467 1. United Nations Development Economic and Social Affairs. World Urbanization
468 Prospects: The 2018 Revision. New York; 2019.
- 469 2. <https://bing.com/covid>. [Cited 2021 Nov 24]
- 470 3. Lowcock EC, Rosella LC, Foisy J, McGeer A, Crowcroft N. The social determinants of
471 health and pandemic h1n1 2009 influenza severity. *Am J Public Health*.
472 2012;102(8):51–8.
- 473 4. Mayoral JM, Alonso J, Garín O, Herrador Z, Astray J, Baricot M, et al. Social factors
474 related to the clinical severity of influenza cases in Spain during the A (H1N1) 2009
475 virus pandemic. *BMC Public Health*. 2013;118(13):1–7.
- 476 5. Grantz KH, Rane MS, Salje H, Glass GE, Schachterle SE, Cummings DAT.
477 Disparities in influenza mortality and transmission related to sociodemographic factors
478 within Chicago in the pandemic of 1918. *Proc Natl Acad Sci U S A*.
479 2016;113(48):13839–44.
- 480 6. Mamelund SE. A socially neutral disease? Individual social class, household wealth
481 and mortality from Spanish influenza in two socially contrasting parishes in Kristiania
482 1918-19. *Soc Sci Med*. 2006;62(4):923–40.
- 483 7. Fallah MP, Skrip LA, Gertler S, Yamin D, Galvani AP. Quantifying Poverty as a Driver
484 of Ebola Transmission. *PLoS Negl Trop Dis*. 2015;9(12):1–9.
- 485 8. Seligman B, Ferranna M, Bloom DE. Social determinants of mortality from COVID-19:
486 A simulation study using NHANES. *PLoS Med*. 2021;18(1):1–13.
- 487 9. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al.
488 Factors associated with hospital admission and critical illness among 5279 people
489 with coronavirus disease 2019 in New York City: Prospective cohort study. *BMJ*.
490 2020;369.
- 491 10. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et
492 al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients
493 Hospitalized with COVID-19 in the New York City Area. *JAMA - J Am Med Assoc*.
494 2020;323(20):2052–9.
- 495 11. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities
496 associated with mortality in 31,461 adults with COVID-19 in the United States: A
497 federated electronic medical record analysis. *PLoS Med*. 2020;17(9):1–11.
- 498 12. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al.
499 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO
500 Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ*.
501 2020;369(March):1–12.
- 502 13. Surendra H, IRF Elyazar, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al.

- 503 Clinical characteristics and mortality associated with COVID-19 in Jakarta ,
504 Indonesia : A hospital-based retrospective cohort study. *Lancet Reg Heal - West*
505 *Pacific*. 2021;9:100108.
- 506 14. Karmakar M, Lantz PM, Tipirneni R. Association of Social and Demographic Factors
507 with COVID-19 Incidence and Death Rates in the US. *JAMA Netw Open*.
508 2021;4(1):1–12.
- 509 15. Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M.
510 Socioeconomic status determines COVID-19 incidence and related mortality in
511 Santiago, Chile. *Science (80-)*. 2021;372(6545).
- 512 16. Oliveira EA, Colosimo EA, Simões e Silva AC, Mak RH, Martelli DB, Silva LR, et al.
513 Clinical characteristics and risk factors for death among hospitalised children and
514 adolescents with COVID-19 in Brazil: an analysis of a nationwide database. *Lancet*
515 *Child Adolesc Heal*. 2021;5(8):559–68.
- 516 17. Sousa BLA, Brentani A, Costa Ribeiro CC, Dolhnikoff M, Grisi SJFE, Ferrer APS, et
517 al. Non-communicable diseases, sociodemographic vulnerability and the risk of
518 mortality in hospitalised children and adolescents with COVID-19 in Brazil: a cross-
519 sectional observational study. *BMJ Open*. 2021;11(9):e050724.
- 520 18. Chen JT, Krieger N. Revealing the unequal burden of COVID-19 by income,
521 race/ethnicity, and household crowding: US county versus zip code analyses. *J Public*
522 *Heal Manag Pract*. 2021;27(1):S46–56.
- 523 19. [https://www.bps.go.id/dynamic/table/2020/02/17/1771/indeks-pembangunan-manusia-](https://www.bps.go.id/dynamic/table/2020/02/17/1771/indeks-pembangunan-manusia-menurut-kabupaten-kota-metode-baru-2010-2019.html)
524 [menurut-kabupaten-kota-metode-baru-2010-2019.html](https://www.bps.go.id/dynamic/table/2020/02/17/1771/indeks-pembangunan-manusia-menurut-kabupaten-kota-metode-baru-2010-2019.html). [Cited 2021 Sep 15].
- 525 20. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
526 real time. *Lancet Infect Dis*. 2020;20(5):533–4.
- 527 21. <https://corona.jakarta.go.id/id/data-pemantauan>. [Cited 2021 Nov 23].
- 528 22. <https://covid19.go.id>. [Cited 2021 Nov 23].
- 529 23. Dyer O. Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant
530 spreads. *BMJ*. 2021;374(July):n1815.
- 531 24. Agustina R, Dartanto T, Sitompul R, Susiloretni KA, Suparmi, Achadi EL, et al.
532 Universal health coverage in Indonesia: concept, progress, and challenges. *Lancet*.
533 2019;393(10166):75–102.
- 534 25. Kementrian Kesehatan Republik Indonesia. Pedoman COVID REV-5. Vol. 1,
535 Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Jakarta:
536 Ministry of Health Indonesia; 2020. 1–125 p.
- 537 26. <https://data.jakarta.go.id/>. [Cited 2021 Sep 15].
- 538 27. <http://bdt.tnp2k.go.id/sebaran/>. [Cited 2021 Sep 15].
- 539 28. Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for

540 COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence
541 setting in South Africa: a cohort study. *Lancet HIV*. 2021;8(9):e554–67.

542 29. Victora PC, Castro PMC, Gurzenda S, Medeiros AC, França GVA, Barros PAJD.
543 Estimating the early impact of vaccination against COVID-19 on deaths among elderly
544 people in Brazil: Analyses of routinely-collected data on vaccine coverage and
545 mortality. *EClinicalMedicine*. 2021;38.

546 30. Sah P, Moghadas SM, Vilches TN, Shoukat A, Singer BH, Hotez PJ, et al.
547 Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas.
548 *Lancet Infect Dis*. 2021;21(11):1493–4.

549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576

577
578

Table 1: Individual, community, health care characteristics and outcomes of COVID-19 cases in DKI Jakarta, March 2, 2020 to August 31, 2021

	Total n=705,503	Deceased n=10,797	Recovered n=694,706	p value
Individual-level characteristics				
Median age (IQR), years	36 (24–50)	59 (50-68)	35 (24-49)	<0.0001
Age group, years				<0.0001
0-4	21,793 (3.1%)	47 (0.4%)	21,746 (3.1%)	
5-9	23,070 (3.3%)	16 (0.2%)	23,054 (3.3%)	
10-19	66,514 (9.4%)	72 (0.7%)	66,514 (9.4%)	
20-29	149,267 (21.2%)	311 (2.9%)	148,956 (21.4%)	
30-39	146,900 (20.8%)	692 (6.4%)	146,208 (21.1%)	
40-49	121,454 (17.2%)	1,455 (13.5%)	119,999 (17.2%)	
50-59	98,934 (14.0%)	3,115 (28.9%)	95,819 (13.8%)	
60-69	52,776 (7.5%)	2,827 (26.2%)	49,949 (7.2%)	
≥70	24,761 (3.5%)	2,261 (20.9%)	22,500 (3.2%)	
Sex				<0.0001
Female	364,133 (51.6%)	4,810 (44.6%)	359,323 (51.7%)	
Male	341,370 (48.4%)	5,987 (55.4%)	335,383 (48.3%)	
Hospitalised				<0.0001
No	472,478 (67.0%)	105 (1.0%)	427,373 (68.0%)	
Yes	233,025 (33.0%)	10,692 (99.0%)	222,333 (32.0%)	
Comorbidities				<0.0001
Absent	288,228 (40.9%)	2,754 (25.5%)	285,474 (41.1%)	
Present	4,974 (0.7%)	468 (4.3%)	4,506 (0.7%)	
Unknown	412,301 (58.4%)	7,575 (70.2%)	404,726 (58.3%)	
Period of time				<0.0001
First wave	321,734 (46.3%)	6,107 (57.1%)	315,627 (46.2%)	
Second wave	372,688 (53.7%)	4,585 (42.9%)	368,103 (53.8%)	
Sub-district-level characteristics*				
Socio-demographics				
Population density, population/Km ²				<0.0001
Q1 (<14,093)	157,561 (22.4%)	2,164 (20.1%)	155,397 (22.4%)	
Q2 (14,093-17,092)	199,848 (28.4%)	2,939 (27.3%)	196,909 (28.4%)	
Q3 (17,092-22,578)	194,519 (27.6%)	3,154 (29.2%)	191,365 (27.6%)	
Q4 (22,578-50,829)	152,557 (21.6%)	2,529 (23.4%)	150,028 (21.6%)	
Poverty, %				<0.0001
Q1 (0.2-1.5)	199,916 (28.4%)	2,717 (25.2%)	197,199 (28.4%)	
Q2 (1.5-2.1)	156,153 (22.1%)	2,614 (24.2%)	153,539 (22.1%)	
Q3 (2.1-3.6)	173,167 (24.6%)	2,712 (25.2%)	170,455 (24.6%)	
Q4 (3.6-8.8)	175,249 (24.9%)	2,743 (25.4%)	172,506 (24.9%)	
Poor sanitation areas, %				0.135
Q1 (0-47.9)	181,868 (25.8%)	2,747 (25.5%)	179,121 (25.8%)	
Q2 (47.9-59.9)	191,093 (27.2%)	2,846 (26.4%)	188,247 (27.2%)	
Q3 (59.9-63.8)	158,002 (22.4%)	2,464 (22.8%)	155,538 (22.4%)	
Q4 (63.8-89.2)	173,522 (24.6%)	2,729 (25.3%)	170,793 (24.6%)	
Health care capacity				
Doctor-population ratio, doctor per 10,000 population				0.158
Q1 (2.6-5.2)	177,254 (25.2%)	2,680 (24.8%)	174,574 (25.2%)	
Q2 (5.2-7.9)	191,918 (27.2%)	3,012 (27.9%)	188,906 (27.2%)	
Q3 (7.9-9.9)	166,147 (23.6%)	2,467 (22.9%)	163,680 (23.6%)	
Q4 (9.9-74.8)	169,166 (24.0%)	2,627 (24.4%)	166,539 (24.0%)	
Nurse-population ratio, nurse per 10,000 population				0.007

Q1 (2.9-11.2)	185,251 (26.3%)	2,755 (25.5%)	182,496 (26.3%)	
Q2 (11.2-22.8)	161,767 (23.0%)	2,553 (23.7%)	159,214 (23.0%)	
Q3 (22.8-83.9)	176,863 (25.1%)	2,611 (24.2%)	174,252 (25.1%)	
Q4 (83.9-416.1)	180,604 (25.6%)	2,867 (26.6%)	177,737 (25.6%)	
COVID-19 vaccination coverage, %				<0.0001
Q1 (33.0-36.1)	190,502 (27.0%)	3,254 (30.2%)	187,248 (27.0%)	
Q2 (36.1-38.5)	164,821 (23.4%)	2,662 (24.7%)	162,159 (23.4%)	
Q3 (38.5-40.5)	172,210 (24.5%)	2,358 (21.8%)	169,852 (24.5%)	
Q4 (40.5-50.0)	176,952 (25.1%)	2,512 (23.3%)	174,440 (25.1%)	
Universal child immunization coverage, %				<0.0001
Q1 (94.5-96.2)	180,820 (25.7%)	2,682 (24.9%)	178,138 (25.7%)	
Q2 (96.2-98.0)	191,987 (27.2%)	2,862 (26.5%)	189,125 (27.2%)	
Q3 (98.0-98.9)	155,023 (22.0%)	2,586 (24.0%)	152,437 (22.0%)	
Q4 (98.9-100.0)	173,999 (25.1%)	2,656 (24.6%)	173,999 (25.1%)	
Health related characteristics				
Prevalence of Hypertension, %				0.490
Q1 (4.2-7.1)	173,268 (24.6%)	2,693 (25.0%)	170,575 (24.6%)	
Q2 (7.1-8.7)	203,932 (29.0%)	3,127 (29.0%)	200,805 (28.9%)	
Q3 (8.7-13.6)	145,395 (20.6%)	2,165 (20.0%)	143,230 (20.7%)	
Q4 (13.6-33.0)	181,890 (25.8%)	2,801 (26.0%)	179,089 (25.8%)	
Prevalence of Diabetes, %				<0.0001
Q1 (0.6-1.3)	188,051 (26.0%)	2,934 (27.2%)	180,117 (26.0%)	
Q2 (1.3-2.1)	160,975 (22.9%)	2,284 (21.2%)	158,691 (22.9%)	
Q3 (2.1-3.2)	176,348 (25.0%)	2,682 (24.9%)	173,666 (25.0%)	
Q4 (3.2-5.4)	184,111 (26.1%)	2,886 (26.7%)	181,225 (26.1%)	
Prevalence of Tuberculosis, %				<0.0001
Q1 (0.1-0.2)	181,457 (25.8%)	2,504 (23.2%)	178,953 (25.8%)	
Q2 (0.2-0.3)	188,309 (26.7%)	2,865 (26.6%)	185,444 (26.7%)	
Q3 (0.3-0.5)	171,319 (24.3%)	2,741 (25.4%)	168,578 (24.3%)	
Q4 (0.5-2.4)	163,400 (23.2%)	2,676 (24.8%)	160,724 (23.2%)	
All-cause mortality per 1000 under 5 years old population				<0.0001
Q1 (0.8-2.1)	201,666 (28.6%)	3,167 (29.4%)	198,499 (28.6%)	
Q2 (2.1-2.6)	137,785 (19.6%)	2,054 (19.0%)	135,731 (19.6%)	
Q3 (2.6-4.0)	204,265 (29.0%)	2,872 (26.6%)	201,393 (29.0%)	
Q4 (4.0-6.3)	160,769 (22.8%)	2,693 (25.0%)	158,076 (22.8%)	

579 First wave: March 2020 to April 2021, Second wave: May 2021 to August 2021. *Numeric
580 values were categorised into quarters (Q), i.e., below 25th percentile (Lowest), 25th–50th
581 percentile (Q2), 50th–75th percentile (Q3) and above 75th percentile (Highest) for each sub-
582 district level variable.
583

584 **Table 2: Bivariable analysis of individual, community, and health care risk factors**
585 **associated with COVID-19 mortality in DKI Jakarta, March 2, 2020 to August 31, 2021**


	Crude OR (95% CI)	p value
Individual-level factors		
Age group, years		
0-4	1.03 (0.76-1.40)	0.836
5-9	0.33 (0.20-0.55)	<0.0001
10-19	0.52 (0.40-0.67)	<0.0001
20-29	1 (ref)	..
30-39	2.27 (1.99-2.60)	<0.0001
40-49	5.81 (5.14-6.57)	<0.0001
50-59	15.59 (13.86-17.52)	<0.0001
60-69	27.26 (24.23-30.67)	<0.0001

≥70	49.18 (43.63-55.43)	<0.0001
Sex		
Female	1 (ref)	..
Male	1.34 (1.28-1.39)	<0.0001
Comorbidities		
Present	10.75 (9.70-11.91)	<0.0001
Absent	1 (ref)	
Period of time		
First wave	1.55 (1.49-1.61)	<0.0001
Second wave	1 (ref)	
Socio-demographics		
Population density		
Lowest	1 (ref)	..
Q2	1.06 (0.96-1.18)	0.229
Q3	1.16 (1.04-1.28)	0.007
Highest	1.20 (1.08-1.33)	0.001
Poverty level		
Lowest	1 (ref)	..
Q2	1.21 (1.09-1.34)	<0.0001
Q3	1.15 (1.04-1.27)	0.006
Highest	1.15 (1.04-1.27)	0.005
Proportion of poor sanitation areas		
Lowest	1 (ref)	..
Q2	0.98 (0.87-1.10)	0.744
Q3	1.15 (1.04-1.27)	0.526
Highest	1.15 (1.04-1.27)	0.664
Health care capacity		
Vaccination coverage		
Lowest	1.20 (1.09-1.31)	<0.0001
Q2	1.14 (1.04-1.24)	0.005
Q3	0.96 (0.88-1.06)	0.423
Highest	1 (ref)	..
Doctor-population ratio		
Lowest	0.97 (0.87-1.10)	0.691
Q2	1.01 (0.90-1.12)	0.899
Q3	0.95 (0.85-1.07)	0.433
Highest	1 (ref)	..
Nurse-population ratio		
Lowest	0.94 (0.84-1.05)	0.292
Q2	0.99 (0.88-1.11)	0.831
Q3	0.94 (0.84-1.05)	0.278
Highest	1 (ref)	..
Universal child immunization		
Lowest	1.00 (0.90-1.12)	0.980
Q2	1.10 (0.97-1.24)	0.131
Q3	1.03 (0.92-1.15)	0.666
Highest	1 (ref)	..
Health related characteristics		
Prevalence of hypertension		
Lowest	1 (ref)	..
Q2	0.97 (0.86-1.09)	0.628
Q3	0.97 (0.86-1.10)	0.685
Highest	1.00 (0.89-1.12)	0.999
Prevalence of diabetes		
Lowest	1 (ref)	..
Q2	0.89 (0.80-1.01)	0.292
Q3	0.96 (0.86-1.07)	0.831
Highest	0.97 (0.86-1.08)	0.278

Prevalence of tuberculosis		
Lowest	1 (ref)	..
Q2	1.10 (0.99-1.22)	0.078
Q3	1.12 (1.00-1.25)	0.044
Highest	1.18 (1.06-1.31)	0.003
All-cause mortality among under 5 years old population		
Lowest	1 (ref)	..
Q2	0.95 (0.86-1.06)	0.398
Q3	0.90 (0.82-1.00)	0.045
Highest	1.07 (0.96-1.19)	0.209

586 OR=odds ratio. First wave=March 2020 to April 2021. Second wave=May 2021 to August
587 2021. Numeric values were categorised into quarters (Q), i.e., below 25th percentile
588 (Lowest), 25th–50th percentile (Q2), 50th–75th percentile (Q3) and above 75th percentile
589 (Highest) for each sub-district level variable.

Pandemic inequity in a megacity: a multilevel analysis of individual, community and health care vulnerability risks for COVID-19 mortality in Jakarta, Indonesia










Fig. 1 Study sites (A), and flow chart and completeness of key variables (B).



C



D








Fig. 2 Characteristics of study sites. Sites categorised based on sub-district population density (A), poverty level (B), COVID-19 vaccine coverage per August 31 2021 (C), overall case fatality rate (D), case fatality rate during the first wave (E), and case fatality rate during the second wave (F). Black lines represent the sub-district administrative border.







Fig. 3 Overall case fatality rate (CFR) by sub-district (A), age-specific CFR per sub-district and by pandemic wave (B), and correlation between CFR with sub-district population density, poverty, and COVID-19 vaccine coverage by epidemic wave (C).






Fig. 4 Final multi-level logistic regression model showing individual, community, and health care factors associated with COVID-19 mortality (A), and age-specific COVID-19 mortality risk over time (B) in DKI Jakarta, Indonesia, March 2, 2020 to August 31, 2021. Sub-district was treated as the random effect variable in both models. For analysis presented in Figure A, first wave=March 2020 to April 2021. Second wave=May 2021 to August 2021. Numeric values were categorised into quartiles (Q), i.e., below 25th percentile (Lowest), 25th–50th percentile (Q2), 50th–75th percentile (Q3) and above 75th percentile (Highest) for each sub-district level variable. For Figure B, each line represents age-specific odds ratio estimates obtained from restricted cubic spline multi-level logistic regression model.

Supplementary data

Table S1: Age-specific mortality with confidence limits in COVID-19 cases in Jakarta, Indonesia, March 2, 2020 to August 31, 2021

Age group (years)	N total	N deceased	% deceased	95% CI
0-4	21,793	47	0.22	0.16-0.29
5-9	23,070	16	0.07	0.04-0.11
10-19	66,514	72	0.11	0.09-0.14
20-29	149,267	311	0.21	0.19-0.23
30-39	146,900	692	0.47	0.44-0.51
40-49	121,454	1,455	1.20	1.14-1.26
50-59	98,934	3,115	3.15	3.04-3.26
60-69	52,776	2,827	5.36	5.17-5.55
70-79	24,261	2,261	9.13	8.78-9.50

Table S2: Sensitivity analysis of individual and community-level risk factors associated with COVID-19 mortality in Jakarta, Indonesia, March 2, 2020 to August 31, 2021

	Adjusted OR (95% CI)	p value
Individual factors		
Age group, years		
0-4	0.71 (0.44-1.14)	0.154
5-9	0.30 (0.15-0.59)	<0.0001
10-19	0.50 (0.36-0.71)	<0.0001
20-29	1 (ref)	..
30-39	1.97 (1.64-2.36)	<0.0001
40-49	4.41 (3.73-5.22)	<0.0001
50-59	11.75 (10.03-13.76)	<0.0001
60-69	17.22 (14.65-20.25)	<0.0001
≥70	30.53 (25.91-35.99)	<0.0001
Sex		
Female	1 (ref)	..
Male	1.29 (1.24-1.34)	<0.0001
Comorbidities		
No	1 (ref)	..
Yes	4.25 (3.81-4.75)	<0.0001
Period of time		
First wave	0.87 (0.69-1.09)	0.215
Second wave	1 (ref)	..
Community (sub-district)-level factors		
Population density		
Lowest	1 (ref)	..
Q2	1.18 (1.03-1.35)	0.017
Q3	1.22 (1.06-1.40)	0.005
Highest	1.32 (1.14-1.54)	<0.0001
Poverty level		
Lowest	1 (ref)	..
Q2	1.39 (1.15-1.67)	0.001
Q3	1.33 (1.16-1.52)	<0.0001
Highest	1.16 (0.97-1.40)	0.109
Vaccine coverage		
Lowest	1.23 (1.13-1.35)	<0.0001
Q2	1.18 (1.09-1.28)	<0.0001
Q3	1.03 (0.90-1.18)	0.059
Highest	1 (ref)	..

Table S2 presents the final multi-level multivariable logistic regression with multiple imputations for missing comorbidities. Sub-district was treated as the random effect variable. First wave: March 2020 to April 2021, Second wave: May 2021 to August 2021. Numeric values were categorised into quartiles (Q), i.e., below 25th percentile (Lowest), 25th–50th percentile (Q2), 50th–75th percentile (Q3) and above 75th percentile (Highest) for each sub-district level variable.

Table S3: Multivariable analysis of effect of age on mortality associated with COVID-19 mortality in Jakarta, Indonesia, March 2, 2020 to August 31, 2021

	First wave		Second wave	
	Adjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value
Age group, years				
0-4	1.56 (1.04-2.35)	0.033	0.72 (0.45-1.16)	0.183
5-9	0.41 (0.19-0.88)	0.022	0.31 (0.16-0.61)	0.001
10-19	0.53 (0.35-0.80)	0.003	0.52 (0.37-0.72)	<0.0001
20-29	1 (ref)	..	1 (ref)	..
30-39	2.48 (2.03-3.04)	<0.0001	1.97 (1.64-2.36)	<0.0001
40-49	6.87 (5.70-8.29)	<0.0001	4.50 (3.80-5.32)	<0.0001
50-59	17.72 (14.80-21.22)	<0.0001	12.33 (10.52-14.44)	<0.0001
60-69	32.81 (27.39-39.29)	<0.0001	18.37 (15.64-21.58)	<0.0001
≥70	58.99 (49.11-70.86)	<0.0001	33.45 (28.41-39.38)	<0.0001

Table S3 presents the time-specific effect of age on mortality, after controlling for sex, comorbidities, population density, poverty, and vaccine coverage, and correlation at sub-district level (random effect variable). OR=odds ratio. First wave=March 2020 to April 2021. Second wave=May 2021 to August 2021.

Table S4: Effect of poverty level on COVID-19 mortality based on population density

	Adjusted OR (95% CI)	p value
Lowest density		
Lowest poverty	1 (ref)	..
Q2	1.43 (1.17-1.75)	<0.0001
Q3	1.35 (1.34-0.77)	<0.0001
Highest poverty	1.18 (0.97-1.43)	0.093
Q2		
Lowest poverty	1.20 (1.04-1.39)	0.012
Q2	1.12 (0.94-1.34)	0.192
Q3	1.34 (1.16-1.55)	<0.0001
Highest poverty	1.25 (1.08-1.45)	0.003
Q3		
Lowest poverty	1.23 (1.06-1.42)	0.006
Q2	1.37 (1.18-1.58)	<0.0001
Q3	NA	NA
Highest poverty	1.23 (1.05-1.45)	0.011
Highest density		
Lowest poverty	1.34 (1.14-1.58)	<0.0001
Q2	1.42 (1.15-1.75)	0.001
Q3	1.24 (1.06-1.45)	0.008
Highest poverty	1.27 (1.10-1.47)	0.001

Table S4 presents the effect of poverty on mortality based on population density, after controlling for sex, comorbidities, time period, vaccine coverage, and correlation at sub-district level (random effect variable). OR=odds ratio. First wave=March 2020 to April 2021.

Second wave=May 2021 to August 2021. First wave: March 2020 to April 2021, Second wave: May 2021 to August 2021.

Table S5: Association between population density with poverty, prevalence of hypertension, diabetes, and tuberculosis

	Population density				p value
	Lowest	Q2	Q3	Highest	
Poverty					
Lowest	35.18%	28.24%	27.84%	22.53%	<0.0001
Q2	11.05%	13.14%	49.16%	11.14%	
Q3	44.38%	28.27%	0.00%	31.02%	
Highest	9.38%	30.34%	23.00%	35.32%	
Hypertension prevalence					
Lowest	27.48%	27.57%	25.19%	17.21%	<0.0001
Q2	27.30%	34.71%	29.29%	22.90%	
Q3	10.88%	22.63%	18.42%	30.62%	
Highest	34.34%	15.09%	27.10%	29.27%	
Diabetes prevalence					
Lowest	14.23%	39.26%	34.31%	10.24%	<0.0001
Q2	34.75%	32.97%	0.00%	26.33%	
Q3	31.75%	5.38%	29.75%	38.09%	
Highest	19.27%	22.39%	35.94%	25.33%	
Tb prevalence					
Lowest	60.29%	0.00%	19.56%	20.15%	<0.0001
Q2	31.09%	27.13%	21.23%	20.54%	
Q3	5.77%	28.43%	40.62%	25.19%	
Highest	9.12%	50.77%	12.65%	27.45%	

Table S5: Association between population density and other covariates. Numeric values were categorised into quartiles (Q), i.e., below 25th percentile (Lowest), 25th–50th percentile (Q2), 50th–75th percentile (Q3) and above 75th percentile (Highest) for each sub-district level variable.

Table S6: Association between poverty with prevalence of hypertension, diabetes, and tuberculosis

	Poverty				p value
	Lowest	Q2	Q3	Highest	
Hypertension prevalence					
Lowest	16.94%	46.95%	27.97%	10.15%	<0.0001
Q2	29.16%	41.99%	12.34%	33.75%	
Q3	42.88%	0.00%	25.97%	8.09%	
Highest	11.03%	11.06%	33.71%	48.01%	
Diabetes prevalence					
Lowest	13.43%	54.05%	27.97%	13.43%	<0.0001
Q2	28.46%	27.44%	20.38%	14.55%	
Q3	40.26%	0.00%	17.94%	37.25%	
Highest	17.85%	18.50%	33.71%	34.77%	
Tb prevalence					
Lowest	37.44%	0.00%	45.83%	15.67%	<0.0001
Q2	38.55%	11.32%	19.29%	33.83%	
Q3	11.03%	53.05%	7.68%	30.56%	
Highest	12.99%	35.63%	27.21%	19.94%	

Table S6: Association between poverty and other covariates. Numeric values were categorised into quartiles (Q), i.e., below 25th percentile (Lowest), 25th–50th percentile (Q2), 50th–75th percentile (Q3) and above 75th percentile (Highest) for each sub-district level variable.




Figure S1. Outcomes over time (A), over age and by gender (B).
Dashed black line represents the cut-off between the first and the second wave.